Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Ted Okerson"'
Autor:
Jennifer A. Rymer, Katherine E. Mues, Keri L. Monda, Emily W. Bratton, Heidi S. Wirtz, Ted Okerson, Robert A. Overman, M. Alan Brookhart, Paul Muntner, Tracy Y. Wang
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 9, Iss 9 (2020)
Background Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are used to reduce low‐density lipoprotein (LDL) cholesterol. PCSK9i use after initiation, as well as persistence with or alterations to other LDL‐lowering therapy after
Externí odkaz:
https://doaj.org/article/aada6edd7f1a471f9a160c2a92af5b56
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 6, Iss 3 (2017)
Background Preceding release of the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol guidelines, prescribers aimed for specific low‐density lipoprotein cholesterol (LDL‐C) goals in patients with atherosclerot
Externí odkaz:
https://doaj.org/article/9d1b23596e0c46e995fd2fdfb285f56d
Publikováno v:
PLoS ONE, Vol 8, Iss 11, p e78971 (2013)
OBJECTIVE: To describe the baseline characteristics in patients who chose placement of a LAP-BAND AP® System (LBAP) and participated in the Helping Evaluate Reduction in Obesity (HERO) Study across regions. PATIENTS AND METHODS: HERO is a five-year,
Externí odkaz:
https://doaj.org/article/2a80a56ac88542479818c09ed64b500d
Autor:
Heidi S. Wirtz, Tracy Y. Wang, Jennifer A. Rymer, Emily W. Bratton, Keri L. Monda, Ted Okerson, M. Alan Brookhart, Paul Muntner, Katherine E Mues, Robert A. Overman
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Proprotein convertase subtilisin/kexin type 9 inhibitors ( PCSK 9i) are used to reduce low‐density lipoprotein ( LDL ) cholesterol. PCSK 9i use after initiation, as well as persistence with or alterations to other LDL ‐lowering therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e869d698e38248c073fc9d93bbbb6ccc
http://europepmc.org/articles/PMC7428552
http://europepmc.org/articles/PMC7428552
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Preceding release of the 2013 American College of Cardiology (ACC)/American Heart Association (AHA) cholesterol guidelines, prescribers aimed for specific low‐density lipoprotein cholesterol (LDL‐C) goals in patients with atherosclerot
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::130bf0450b099f2c5fa513a9a53eea24
https://doi.org/10.1161/jaha.116.004909
https://doi.org/10.1161/jaha.116.004909
Autor:
Daisy S. Ng-Mak, Ted Okerson, David B. Sarwer, Helmuth Billy, Christopher T. Cornell, Jaime Ponce, Rebecca Shi
Publikováno v:
Postgraduate Medicine. 126:131-140
Obesity is often associated with diminished health-related quality of life (HRQOL), but significant gains in HRQOL have been observed after bariatric surgery. Laparoscopic adjustable gastric banding has been established as a safe, effective treatment
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cda98cc1de9d6ca5a7039cc9390a2ea8
https://doi.org/10.3810/pgm.2014.07.2791
https://doi.org/10.3810/pgm.2014.07.2791
Publikováno v:
Current Medical Research and Opinion. 30:849-855
Obesity is one factor associated with an increased risk of obstructive sleep apnea (OSA). This study reports the investigator-reported resolution or improvement of OSA and improvements in sleep-related quality of life (QOL) 2 years after surgical pla
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85eddac2d82ecee1709bab781fbbc26a
https://doi.org/10.1185/03007995.2013.874991
https://doi.org/10.1185/03007995.2013.874991
Autor:
Rui Shi, Jaime Ponce, Daisy S. Ng-Mak, Christopher T. Cornell, Vincent Lusco, Ted Okerson, Shahrad Taheri
Publikováno v:
Current Medical Research and Opinion. 30:841-848
This 48 week combined analysis reports safety and clinical effectiveness of the LAP-BAND AP * laparoscopic adjustable gastric band (LAGB) in severely obese patients enrolled in the 5 year, prospective, observational, open-label APEX (NCT00501085) and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::02720765e64f3336a89529e972096f41
https://doi.org/10.1185/03007995.2013.874992
https://doi.org/10.1185/03007995.2013.874992
Publikováno v:
Advances in Therapy
Background Obesity is a major risk factor for cardiovascular disease (CVD), with weight loss offering improvement in CVD risk factors. Aims To examine whether weight loss in laparoscopic adjustable gastric band (LAGB)-treated obese patients is associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8b3e8617bcdf344912e3a8454a3c215
http://europepmc.org/articles/PMC3747322
http://europepmc.org/articles/PMC3747322
Publikováno v:
Postgraduate Medicine. 124:181-188
The objective of this analysis is to report interim, 2-year results for morbidly obese patients who have undergone laparoscopic adjustable gastric banding in the LAP-BAND AP® EXperience (APEX) trial.The APEX trial is an ongoing, multicenter, prospec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3566cf51d23459b1201cf5189628cd6
https://doi.org/10.3810/pgm.2012.07.2561
https://doi.org/10.3810/pgm.2012.07.2561